Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | TACR3 | P29371 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723790 | 0.88 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL792022 | 0.88 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL7723793 | 0.88 | TAS1R3 (0.56) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL14186870 | 0.86 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL1953141 | 0.86 | TAS1R3 (0.51) | TAS1R3TAS1R1TACR3TSHRNAMPT | |
| SCHEMBL14893136 | 0.86 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL15716619 | 0.86 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL18943197 | 0.86 | TAS1R3 (0.54) | TAS1R3TAS1R1TACR3TSHRROCK2 | |
| SCHEMBL29367113 | 0.85 | TAS1R3 (0.67) | TAS1R3TAS1R1TACR3ROCK2ROCK1 | |
| SCHEMBL19652271 | 0.85 | TAS1R3 (0.53) | TAS1R3TAS1R1TACR3TSHRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | TAS1R3 491/4885TAS1R1 536/4885TACR3 145/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | TAS1R3 491/4885TAS1R1 536/4885TACR3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.